Spring Bank Pharmaceuticals Inc
Spring Bank Pharmaceuticals — Investor Presentation (September 2017)
28 slides from Spring Bank Pharmaceuticals's investor presentation, Sep 21, 2017
Slide 1: A Novel Pharmaceutical Platform Focused on Selective Immunomodulation
A Novel Pharmaceutical Platform Focused on Selective Immunomodulation
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements, other than historical facts, regarding: the progress, scope, duration or re
Slide 3: Corporate Overview
Corporate Overview Clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using a proprietary small molecule nucleic acid hybrid (SMNH) technology IPO: 2016 Nasdaq: SBPH Market Cap: $200MM1 Available Funding: $56MM2 Shares Outstanding: 12,6
Slide 4: Investment Highlights
Investment Highlights Pipeline of novel, differentiated and proprietary immunomodulatory compounds Lead RIG-I agonist compound: SB 9200 – for chronic HBV Clinical proof-of-concept demonstrated in 1st cohort (Part A) of ongoing ACHIEVE Phase II study Lifecycle management opportunity with further deve
Slide 5: Executive Management Team
Executive Management Team Proven leadership team focused on creating shareholder value MARTIN DRISCOLL President & Chief Executive Officer KRIS IYER, PhD Chief Scientific Officer & Co-Founder NEZAM AFDHAL, MD Chief Medical Officer JONATHAN FREVE, CPA Chief Financial Officer Current Scientific Adviso
Slide 6: Current Pipeline: Opportunities & Development Status
Current Pipeline: Opportunities & Development Status SMNH PLATFORM TARGETS COMPOUND INDICATION RESEARCH PRECLINICAL CLINICAL STATUS RIG-I SB 9200 (oral): HBV Monotherapy ACHIEVE Phase II (Part A) Clinical Trial Ongoing Co-Administration with Gilead’s Viread® ACHIEVE Phase II (Part B) Trial expected
Slide 7: Strategic Focus
Strategic Focus ADVANCE HBV PROGRAM TO PHASE III Global Phase III trials anticipated to begin in 2019 LEVERAGE OUR SMNH PLATFORM RIG-I Agonists: HIV latency and other viral infections STING Agonists and Antagonists: immuno-oncology & autoimmune diseases Creative #:168360022 5 NOVEL COLLABORATIONS Ex
Slide 8: Chronic HBV: A Major Unmet Need and Compelling Commercial Opportunity
Chronic HBV: A Major Unmet Need and Compelling Commercial Opportunity Global Distribution of Chronic HBV Infection Approved therapies for HBV lack a broadly sustained virological response (SVR) following treatment cessation Clearance or loss of HBV surface antigen (HBsAg) required for functional cur
Slide 9: Current HBV Treatments Largely Ineffective at Significantly Reducing/Clearing Surface Antigens
Current HBV Treatments Largely Ineffective at Significantly Reducing/Clearing Surface Antigens DIRECT-ACTING ANTIVIRALS (DAAs) aka “Nucs” e.g. Viread® or Baraclude ® Key Characteristics Needed with Future Treatments: A major opportunity exists for a treatment that can increase “functional cure” rate
Slide 10: SB 9200
SB 9200 Small molecule nucleic acid hybrid (SMNH) Orally bioavailable Hepatic-selective immunomodulator Favorable safety profile – up to 900mg to date Physical properties allow for potential fixed-dose combination with DAAs 8
Slide 11: SB 9200 — An Orally-Available Selective Immunomodulator
SB 9200 — An Orally-Available Selective Immunomodulator Designed to restore innate and adaptive immunity which is down-regulated in chronic virally infected cells Key Characteristics Activates RIG-I and NOD2 — sentinel proteins in the body’s innate defense system Targets the liver Launches adaptive
Slide 12: ACHIEVE Phase II Clinical Study of SB 9200 in HBV
ACHIEVE Phase II Clinical Study of SB 9200 in HBV Clinical trial collaboration with Gilead to evaluate SB 9200 with nucleotide analog VireadÒ 300 mg Phase II (Part A) Phase II (Part B) 12 weeks Placebo SB 9200- 200 mg SB 9200- 100 mg SB 9200- 50 mg SB 9200- 25 mg VireadÒ 300 mg 12 weeks (SB 9200 mon
Slide 13: SB 9200 HBV Phase II Program
SB 9200 HBV Phase II Program 11 ACHIEVE Phase II (Part B) Study SB 9200 Co-administered with VireadÒ (tenofovir disoproxil fumarate) 300mg 12 weeks VireadÒ monotherapy VireadÒ monotherapy SB 9200 - 100 mg + VireadÒ VireadÒ 12 weeks Anticipated initiation in 2H 2018 Gilead Phase II HBV Trial SB 9200
Slide 14: Top-Line Results from the Initial Cohort of the ACHIEVE Phase II (Part A) Study
Top-Line Results from the Initial Cohort of the ACHIEVE Phase II (Part A) Study SB 9200 resulted in a Statistically Significant Reduction in HBV DNA Mean reduction of 0.6 log₁₀(range of 0 to 1.87 log₁₀) p=0.01 (unpaired t-test 2.85) Reached Secondary Endpoint of Quantitative HBsAg Reduction 5 of 16
Slide 15: ACHIEVE Phase II (Part A) Study SB 9200 Responder and Additive Effect of Viread
ACHIEVE Phase II (Part A) Study SB 9200 Responder and Additive Effect of Viread® 300mg 13 Viread® 300mg Undetectable Genotype D1 HBeAg −ve
Slide 16: Interim Observations: No safety signals observed to date
No safety signals observed to date Antiviral effect seen – reductions in HBV DNA, HBV RNA and HBsAg HBeAg-negative patient response may potentially reflect higher HBsAg and HBV DNA load considering low dose of SB 9200 Virological studies of 1st Cohort 25mg Monotherapy from Dr. Stephen Locarnini’s La
Slide 17: Spring Bank Collaborations with Other Investigational MOAs for HBV
Spring Bank Collaborations with Other Investigational MOAs for HBV Potential to demonstrate increased HBV functional cure rates with more favorable tolerability profile and shorter duration of treatment relative to current IFN-based regimens Evaluating SB 9200, co-administered with Gilead’s Vemlidy®
Slide 18: SB 11285
SB 11285 Next-generation STING agonist Cyclic dinucleotide Multiple routes of administration (IT, IV) Distinctive chemistry allows for potential conjugation with ADCs for targeted delivery Shown to be highly potent across multiple cancer models Designed for combinatorial administration to turn “cold
Slide 19: STING Plays a Critical Role in Tumor Immunity
STING (STimulator of INterferon Genes) Plays a Critical Role in Tumor Immunity STING is involved in detecting the presence of tumor cells and promoting an aggressive anti-tumor response by the innate immune system Multiple immune genes including RIG-I and STING are involved in providing protection a
Slide 20: Differentiated Portfolio of SMNH-Platform Derived STING Agonists
Differentiated Portfolio of SMNH-Platform Derived STING Agonists 18 Lead compound SB 11285 is a novel synthetic STING agonist Portfolio of STING agonist compounds that have demonstrated highly potent activity in vitro and in vivo STING dependent IRF (interferon regulatory factor) and NF-KB induction
Slide 21: SB 11285 in Relevant Oncology Models
SB 11285 in Relevant Oncology Models SB 11285 has shown that it significantly inhibits tumor growth in relevant oncology models Efficacy in relevant oncology animal models demonstrated with intratumoral (IT) and intravenous (IV) delivery A20 syngeneic mouse model CT26 Colon Cancer Model Metastatic B
Slide 22: Potent Abscopal antitumoral activity of SB 11285 in CT26 model
Potent Abscopal antitumoral activity of SB 11285 when administered intratumorally in CT26 mouse colorectal carcinoma model 20 SUBCUTANEOUS Tumors implanted on left and Right flanks. 100 ug SB 11285 administered on left flank Left flank tumor growth Right flank tumor growth 1 2 4 6 8 Tumor implant Tu
Slide 23: IP administration of SB 11285 inhibits tumor metastasis in 4T1 model
Intraperitoneal (IP) administration of SB 11285 inhibits tumor metastasis in the 4T1 breast Cancer syngeneic mouse model 21 METASTATIC VEHICLE SB 11285 Animal 1 Animal 2 Animal 6 Animal 2 Animal 5 Animal 6 Day 33 Day 25 Day 40
Slide 24: Systemic SB 11285 shows potent antitumor activity and synergy with anti-CTLA Ab
Systemically administered (i.p. and i.v.) SB 11285 shows potent antitumor activity and is synergistic with anti-CTLA Ab in CT26, a syngeneic mouse colorectal carcinoma model 22 SUBCUTANEOUS Efficacy of i.v. SB 11285 appears better than i.p. SB 11285 Tumor Volume Tumor implant Treatment phase Tumor 1
Slide 25: Potent anti-tumor activity of IV and IP SB 11285 in B16 melanoma model
Potent anti-tumor activity of IV and IP administered SB 11285 in the B16 melanoma syngeneic mouse model 23 SUBCUTANEOUS Mean tumor volume following three doses of SB 11285 on Days 1, 3 and 8 at 9 mg/kg Tumor Volume Tumor implant Treatment phase Tumor 100 mm3 Days SB 11285Day 1 3 8 Tumor volume (mm3)
Slide 26: SB 11285 – A Next-Generation STING Agonist
SB 11285 – A Next-Generation STING Agonist Key Characteristics of SB 11285 24 SB 11285 Observations and Distinctions Well-tolerated Potent and durable antitumor response via IT, IP & IV administration in multiple cancer models Potentially synergistic with other anti-cancer agents IT IP & IV dose res
Slide 27: Achieved/Anticipated Milestones for Spring Bank
1H 2018: Gilead to initiate Phase II study (SB 9200 + Vemlidy®) Achieved/Anticipated Milestones for Spring Bank — Potential for Multiple Catalysts 25 2017 2018 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 1H 2017: Released top-line results for the 1st Cohort (25mg monotherapy dosing) from the SB 9200 ACHIEVE Phase II (P
Slide 28: Spring Bank Pharmaceuticals, Inc. Investment Opportunity
Spring Bank Pharmaceuticals, Inc. Investment Opportunity NASDAQ: SBPH Differentiated SMNH Platform Technology Clinical-stage with Phase II Proof-of-Concept achieved for SB 9200 in HBV Next-generation STING agonist program SB 11285 anticipated to enter clinic in liver cancers in 2018 Anticipate multi
Spring Bank Pharmaceuticals — Investor Presentation (September 2017) on 6ix